Home   Business   Article

How F-star could earn milestone payments of up to $447m after Denali Therapeutics deal


By Paul Brackley


John Haurum, CEO of F-star
John Haurum, CEO of F-star

F-star Gamma acquired early by San Francisco firm for $24m

F-star is based on Babraham Research Campus
F-star is based on Babraham Research Campus

F-star has secured an upfront payment of $24million – and is in line for potential milestone payments worth up to $447million – after Denali Therapeutics chose to exercise its early option to acquire F-star Gamma.

The biopharmaceutical firm, based on Babraham Research Campus, is developing novel bispecific antibodies – drugs that can have two targets. It wraps up its drugs programmes into new entities – asset-centric vehicles – that can be sold off without negatively impacting the rest of the pipeline.

F-star has been collaborating with San Francisco-based Denali since August 2016 to develop Fcabs – an antibody fragment that can be used as a building block – that enable biologic therapies to be delivered across the blood-brain barrier.

Denali now has the exclusive rights to these Fcabs, for which it is paying $24million plus any net cash held by F-star Gamma. Further payments of up to $447m are contingent on the achievement of future milestones.

Scientists at work at F-star
Scientists at work at F-star

Denali has also exercised its right to nominate the two remaining Fcab targets under the original deal.

John Haurum, CEO of F-star, said: “Denali’s early exercise of its option to acquire F-star Gamma is testimony to the progress of our collaboration. We are delighted that our Modular Antibody Technology is being applied to address significant unmet needs beyond F-star’s therapeutic focus in immuno-oncology.”

Ryan Watts, CEO of Denali Therapeutics, said: “Our decision to exercise the option to buy F-star Gamma reflects the progress in our collaboration with F-star and the generation of data showing that our proprietary transport vehicle platform technology will enable us to deliver biologics across the blood brain barrier (BBB) and into the brain. Furthermore, the expanded collaboration allows us to deepen and broaden our research efforts supporting our BBB platform technology.”

F-star said it will invest its proceeds from the transaction in progressing its proprietary pipeline of first-in-class immuno-oncology bispecific antibodies through clinical development.

F-star is developing bispecific antibodies
F-star is developing bispecific antibodies

Read more

How F-star is supercharging the immune system in fight against cancer



COMMENTS
()


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.

 

Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More